MEC Practice Academy 11.19
|Articles|October 12, 2012

Trading Away the Medicines of Tomorrow

Author(s)Mike Hennessy

One of the major issues being negotiated right now the amount of protection for the intellectual property of pharmaceutical and biotech companies. And failure to protect the intellectual property rights will actually hurt patients more than the companies.

Click here to view this article.


Related to this article

Sethu Reddy: ©Sethu Reddy
Prior authorization, step therapy and shifting coverage rules keep patients from obesity drugs with proven benefits, an endocrinologist argues — and the long-term savings make the case for broader access.